Unmet needs in the treatment of glioblastoma

Expert Review of Anticancer Therapy

Volumn 9, Issue 5, 2009, Pages 545-551

  Mut, Melike ^a   Schiff, David ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CINTREDEKIN BESUDOTOX; ETIRACETAM; FOTEMUSTINE; IMMUNOTOXIN; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; TEMOZOLOMIDE; TP 38; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AGING; ANTIANGIOGENIC THERAPY; BLOOD TOXICITY; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TARGETING; EDITORIAL; ELDERLY CARE; EPILEPSY; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; INTERMETHOD COMPARISON; MORBIDITY; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; REOPERATION; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE; BRAIN TUMOR; NEEDS ASSESSMENT;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEEDS ASSESSMENT;

EID: 68149137523     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.24     Document Type: Editorial

References (73)

1. Salcman M. Glioblastoma and malignant astrocytoma. In: Brain Tumors: An Encyclopedic Approach. Kaye AH, Laws ER Jr (Eds). Churchill Livingstone, Edinburgh, UK 449-478 (1995).
2. Olson JJ, Ryken T. Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J. Neurooncol. 89(3), 255-258 (2008).
3. Wrensch M, Minn Y, Chew T et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro. Oncol. 4, 278-299, (2002).
4. Chakrabarti I, Cockburn M, Cozen W et al. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 104, 2798-2806 (2005).
5. Elia-Pasquet S, Provost D, Jaffre A et al. Incidence of central nervous system tumors in Gironde, France. Neuroepidemiology 23, 110-117 (2004).
6. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro. Oncol. 8, 27-37 (2006).
7. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
8. Iwamoto FM, Reiner AS, Panageas KS et al. Patterns of care in elderly glioblastoma patients. Ann. Neurol. 64(6), 628-634 (2008).
9. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356(15), 1527-1535 (2007).
10. Idbaih A, Taillibert S, Simon JM et al. Short course of radiation therapy in elderly patients with glioblastoma multiforme. Cancer Radiother. 12(8), 788-792 (2008).
11. Minniti G, De Sanctis V, Muni R et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J. Neurooncol. 91(1), 95-100 (2009).
12. Shaffrey ME, Mut M, Asher AL et al. Brain metastases. Curr. Probl. Surg. 41(8), 665-741 (2004).
13. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109 (2007).
14. Campos S, Davey P, Hird A et al. Brain metastasis from an unknown primary, or primary brain tumour? A diagnostic dilemma. Curr. Oncol. 16(1), 62-66 (2009).
15. Schiff D. Single brain metastasis. Curr. Treat. Options Neurol. 3, 89-99 (2001).
16. McMillan KM, Ehtesham M, Stevenson RT et al. T2 detection of tumor invasion within segmented components of glioblastoma multiforme. J. Magn. Resort. Imaging 29(2), 251-257 (2009).
17. Wang S, Kim S, Chawla S et al. Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage 44(3), 653-660 (2009).
18. García-Gómez JM, Luts J, Julià-Sapé M et al. Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy. MAGMA 22(1), 5-18 (2009).
19. Wang W, Steward CE, Desmond PM: Diffusion tensor imaging in glioblastoma multiforme and brain metastases: the role of p, q, l, and fractional anisotropy. AJNR Am. J. Neuroradiol. 30, 203-208 (2009).
20. Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J. Clin. Oncol. 27(8), 1275-1279 (2009).
21. Preusser M. MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol. Histopathol. 24(4), 511-518 (2009).
22. Murat A, Migliavacca E, Gorlia T et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26(18), 3015-3024 (2008).
23. Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg. Neurol. 52, 371-379 (1999).
24. Kowalczuk A, Macdonald RL, Amidei C et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41, 1028-1038 (1997).
25. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190-198 (2001).
26. Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29, 385-389 (1991).
27. Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J. Neurosurg. 73, 331-344 (1990).
28. Metcalfe SE, Grant R: Biopsy versus resection for malignant glioma. Cochrane Database Syst. Rev. 3, CD002034 (2005).
29. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J. Neurooncol. 42, 227-231 (1999).
30. McGirt MJ, Chaichana KL, Gathinji M et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J. Neurosurg. 110(1), 156-162 (2009).
31. Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34, 45-61 (1994).
32. Stummer W, Novotny A, Stepp H et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. 93(6), 1003-1013 (2000).
33. Siomin V, Barnett G. Intraoperative imaging in glioblastoma resection. Cancer J. 9(2), 91-98 (2003).
34. Stummer W, Pichlmeier U, Meinel T et al. ALA Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol. 7, 392-401 (2006).
35. Pichlmeier U, Bink A, Schackert G et al. ALA Glioma Study Group. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro. Oncol. 10(6), 1025-1034 (2008).
36. Barbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate? Br. J. Neurosurg. 22(3), 452-455 (2008).
37. Barker FG, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42, 709-720 (1998).
38. Ryken TC, Frankel B, Julien T et al. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J. Neurooncol. 89(3), 271-286 (2008).
39. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345, 1008-1012 (1995).
40. Von Eckardstein KL, Reszka R, Kiwit JC. Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma - clinical observations. J. Neurooncol. 74(3), 305-309 (2005).
41. Stylli SS, Kaye AH, MacGregor L et al. Photodynamic therapy of high grade glioma - long term survival. J. Clin. Neurosci. 12, 389-398 (2005).
42. Kunwar S, Westphal M, Medhorn M et al. Results from precise: a randomized Phase 3 study in patients with first recurrent glioblastoma multiforme (GBM) comparing cintredekin besudotox (RT) administered via convection-enhanced delivery (CED) with gliadel wafers (GW). Presented at: The 12th Annual Meeting of the Society for Neuro-Oncology. Dallas, TX, USA, 15-18 November 2007.
43. Mut M, Sherman JH, Shaffrey ME et al. Cintredekin besudotox in treatment of malignant glioma. Expert Opin Biol. Ther. 8(6), 805-812 (2008).
44. Sampson JH, Akabani G, Archer GE et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro. Oncol. 10(3), 320-329 (2008).
45. Dillman RO, Duma CM, Schiltz PM et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J. Immunother. 27, 398-404 (2004).
46. Prados MD, McDermott M, Chang SM et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a Phase I/II multi-institutional trial. J. Neurooncol. 65, 269-278 (2003).
47. McGirt MJ, Than KD, Weingart JD et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J. Neurosurg. 110(3), 583-588 (2009).
48. Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 60(3), 853-860 (2004).
49. Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer 88, 1004-1011 (2003).
50. Dall'oglio S, D'Amico A, Pioli F et al. Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. J. Neurooncol. 90(3), 315-319 (2008).
51. Glas M, Happold C, Rieger J et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J. Clin. Oncol. 27(8), 1257-1261 (2009).
52. Nieder C, Adam M, Molls M et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol. 60(3), 181-193 (2006).
53. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat. Rev. 26, 397-409 (2000).
54. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperative di Neuro-Oncologia (GICNO). J. Clin. Oncol. 22(23), 4779-4786 (2004).
55. Fazeny-Dörner B, Veitl M, Wenzel C et al. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 14(6), 437-442 (2003).
56. Brandes AA, Ermani M, Turazzi S et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a Phase II study. J. Clin. Oncol. 17(2), 645-650 (1999).
57. Fabrini MG, Silvano G, Lolli I et al. A multi-institutional Phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J. Neurooncol. 92(1), 79-86 (2009).
58. Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2008.10.043 (2009).
59. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91(3), 329-336 (2009).
60. Martin V, Liu D, Gomez-Manzano C. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr. Phdrm. Des. 15(4), 353-364 (2009).
61. Blumenthal DT, Won M, Mehta MP et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J. Clin. Oncol. 27(5), 733-739 (2009).
62. Pirzkall A, McGue C, Saraswathy S et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro. Oncol. DOI:10.1215/ 15228517-2009-005 (2009).
63. Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2), 405-410 (2008).
64. Gerstner ER, McNamara MB, Norden AD et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J. Neurooncol. (2009).
65. Peca C, Pacelli R, Elefante A et al. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin. Neurol. Neurosurg. DOI: 10.1016/ j.clineuro.2008.11.003 (2008).
66. Mason WP, Maestro RD, Eisenstat D et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr. Oncol. 14(3), 110-117 (2007).
67. Siomin V, Angelov L, Li L et al. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J. Neurooncol. 74(2), 211-215 (2005).
68. Rosati A, Tomassini A, Pollo B et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations. J. Neurooncol. DOI: 10.1007/s11060-009-9796-5 (2009).
69. Sirven JI, Wingerchuk DM, Drazkowski JF et al. Seizure prophylaxis in patients with brain tumors: a metanalysis. Mayo Clin. Proc. 79, 1489-1494, (2004).
70. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2, 404-409 (2003).
71. Wick W, Menn O, Meisner C et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 28, 391-396 (2005).
72. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J. Neurooncol. 78, 99-102 (2006).
73. Saraswathy S, Crawford FW, Lamborn KR et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J. Neurooncol. 91(1), 69-81 (2009).